Concepedia

Author

G. De Cataldis

Tumour Institute of Tuscany

Also Known As

G De Cataldis, G Frasci, G. De Cataldis, G. De. Cataldis

28

Publications

232

Citations

9

H-Index

15

Concepts

All Affiliations

Tumour Institute of TuscanyUniversity of SassariOspedale S.Gennaro
GD

About

G. De Cataldis is an author at Tumour Institute of Tuscany specializing in cancer therapeutics, oncology, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

144

2

Cancer Therapeutics

7

7

144

3

Pharmacology

6

6

128

4

Health Sciences

1

1

16

5

Clinical Trials

1

1

11

G. De Cataldis

×

7

Publications

144

Citations

7

H-Index

YearCitations

Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101)

P. Comella, Gianfranco Filippelli, G. De Cataldis,

Annals of Oncology

2006

47

Carboplatin–oral etoposide personalised dosing in elderly non-small cell lung cancer patients

G. Frasci, P. Comella, N. Panza,

European Journal of Cancer

1998

26

Addition of either irinotecan or methotrexate to bolus5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group

P. Comella, E. Crucitta, Ferdinando De Vita,

Annals of Oncology

2002

24

Cisplatin-gemcitabine, vs. cisplatin-gemcitabine-vinorelbine, vs. cisplatin-gemcitabine-paclitaxel in advanced non-small-cell lung cancer. First-stage analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial

P. Comella, G. Frasci, N. Panza,

Lung Cancer

2000

16

Gemcitabine + vinorelbine (GV) yields better survival than vinorelbine (V) alone in elderly non-small cell lung cancer (NSCLC) patients. Final analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial

G. Frasci, Vito Lorusso, N. Panza,

Lung Cancer

2000

11

Enhancement of C.E.V combination (cisplatin, epirubicin, vindesine) in advanced NSCLC by lonidamine. A phase II randomized trial

Giovanni Pietro Ianniello, G. De Cataldis, P. Comella,

Lung Cancer

1994

10

Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study

P. Comella, B. Massidda, S. Palmeri,

Cancer Chemotherapy and Pharmacology

2005

10

Page 1